日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment

一项多中心、I期、药代动力学研究，旨在评估奥希替尼在肾功能正常或严重肾功能损害的癌症患者中的药代动力学。

期刊:Pharmacology Research & Perspectives
影响因子:2.3
doi:10.1002/prp2.613
Vishwanathan, Karthick; Sanchez-Simon, Inmaculada; Keam, Bhumsuk; Penel, Nicolas; de Miguel-Luken, Maria; Weilert, Doris; Mills, Andrew; Marotti, Marcelo; Johnson, Martin; Ravaud, Alain
肿瘤
肿瘤免疫
发表日期：2020
文献求助 收藏

The effect of itraconazole and rifampicin on the pharmacokinetics of osimertinib

伊曲康唑和利福平对奥希替尼药代动力学的影响

期刊:British Journal of Clinical Pharmacology
影响因子:3
doi:10.1111/bcp.13534
Vishwanathan, Karthick; Dickinson, Paul A; So, Karen; Thomas, Karen; Chen, Yuh-Min; De Castro Carpeño, Javier; Dingemans, Anne-Marie C; Kim, Hye Ryun; Kim, Joo-Hang; Krebs, Matthew G; Chih-Hsin Yang, James; Bui, Khanh; Weilert, Doris; Harvey, R Donald
发表日期：2018
文献求助 收藏

Effect of multiple-dose osimertinib on the pharmacokinetics of simvastatin and rosuvastatin

多剂量奥希替尼对辛伐他汀和瑞舒伐他汀药代动力学的影响

期刊:British Journal of Clinical Pharmacology
影响因子:3
doi:10.1111/bcp.13753
Harvey, R Donald; Aransay, Noemi Reguart; Isambert, Nicolas; Lee, Jong-Seok; Arkenau, Tobias; Vansteenkiste, Johan; Dickinson, Paul A; Bui, Khanh; Weilert, Doris; So, Karen; Thomas, Karen; Vishwanathan, Karthick
发表日期：2018
文献求助 收藏

Pharmacokinetic equivalence, comparable safety, and immunogenicity of an adalimumab biosimilar product (M923) to Humira in healthy subjects.

在健康受试者中，阿达木单抗生物类似药（M923）与阿达木单抗（Humira）具有药代动力学等效性、可比安全性和免疫原性

期刊:Pharmacology Research & Perspectives
影响因子:2.3
doi:10.1002/prp2.380
Hillson Jan, Mant Tim, Rosano Molly, Huntenburg Carolyn, Alai-Safar Mehrshid, Darne Siddhesh, Palmer Donna, Pavlova Borislava G, Doralt Jennifer, Reeve Russell, Goel Niti, Weilert Doris, Rhyne Paul W, Chance Kamali, Caminis John, Roach James, Ganguly Tanmoy
其它
发表日期：2018
文献求助 收藏